Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313404821> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4313404821 endingPage "64.04" @default.
- W4313404821 startingPage "64.04" @default.
- W4313404821 abstract "Abstract According to the World Health Organization, influenza causes 3–5 million cases of severe illness and 250,000 – 500,000 deaths annually despite the availability of a seasonal vaccine. As an alternative therapy for use in high-risk groups and environments, we evaluated the efficacy of prophylactic treatment with a novel synthetic TLR4 agonist in BALB/c mice. Animals were anesthetized and treated with a TLR4 agonist intranasally (IN) 0 to 28 days prior to a lethal challenge with either H1N1 or H3N2 mouse-adapted human influenza. Animals were monitored daily for weight loss, decreased body temperature, body score, and mortality. Initial dose-response experiments demonstrated that mice treated with 50 μg or 10 μg of our novel TLR4 agonist in an aqueous formulation were similarly protected from H3N2 influenza challenge with respect to weight loss and survival. However, initial weight loss data demonstrated that 50 μg was not as well tolerated as 10 μg. The 10 μg dose was therefore selected as the lead dose in subsequent experiments. In a series of formulation comparison experiments, the lead formulation resulted in marked improvement in both percent weight loss and survival compared to initial TLR4 agonist formulations. Animals treated with all formulations of our novel synthetic TLR4 agonist 0, 7, or 14 days prior to infection resulted in 80–90% survival. The lead formulation also resulted 80–90% survival when given prophylactically 21 or 28 days prior to infection compared to 0–20% survival in untreated mice. Overall, our results show that pre-treatment with our novel synthetic TLR4 agonist prior to exposure to mouse-adapted H1N1 and H2N3 influenza strains reduced morbidity and mortality in infected mice for up to 28 days after treatment. This work was supported by NIH grant 5R44AI136081-03" @default.
- W4313404821 created "2023-01-06" @default.
- W4313404821 creator A5004701028 @default.
- W4313404821 creator A5010391577 @default.
- W4313404821 creator A5023527117 @default.
- W4313404821 creator A5027278009 @default.
- W4313404821 creator A5036036725 @default.
- W4313404821 creator A5037675612 @default.
- W4313404821 creator A5067265214 @default.
- W4313404821 creator A5082093098 @default.
- W4313404821 creator A5083840245 @default.
- W4313404821 creator A5085184610 @default.
- W4313404821 creator A5087354910 @default.
- W4313404821 date "2022-05-01" @default.
- W4313404821 modified "2023-09-25" @default.
- W4313404821 title "Pre-treatment with a novel synthetic TLR4 agonist prior to challenge with mouse-adapted H1N1 and H2N3 influenza strains reduced morbidity and mortality in BALB/c mice" @default.
- W4313404821 doi "https://doi.org/10.4049/jimmunol.208.supp.64.04" @default.
- W4313404821 hasPublicationYear "2022" @default.
- W4313404821 type Work @default.
- W4313404821 citedByCount "0" @default.
- W4313404821 crossrefType "journal-article" @default.
- W4313404821 hasAuthorship W4313404821A5004701028 @default.
- W4313404821 hasAuthorship W4313404821A5010391577 @default.
- W4313404821 hasAuthorship W4313404821A5023527117 @default.
- W4313404821 hasAuthorship W4313404821A5027278009 @default.
- W4313404821 hasAuthorship W4313404821A5036036725 @default.
- W4313404821 hasAuthorship W4313404821A5037675612 @default.
- W4313404821 hasAuthorship W4313404821A5067265214 @default.
- W4313404821 hasAuthorship W4313404821A5082093098 @default.
- W4313404821 hasAuthorship W4313404821A5083840245 @default.
- W4313404821 hasAuthorship W4313404821A5085184610 @default.
- W4313404821 hasAuthorship W4313404821A5087354910 @default.
- W4313404821 hasConcept C126322002 @default.
- W4313404821 hasConcept C147583825 @default.
- W4313404821 hasConcept C170493617 @default.
- W4313404821 hasConcept C203014093 @default.
- W4313404821 hasConcept C2776070231 @default.
- W4313404821 hasConcept C2778938600 @default.
- W4313404821 hasConcept C511355011 @default.
- W4313404821 hasConcept C544821477 @default.
- W4313404821 hasConcept C71924100 @default.
- W4313404821 hasConcept C98274493 @default.
- W4313404821 hasConceptScore W4313404821C126322002 @default.
- W4313404821 hasConceptScore W4313404821C147583825 @default.
- W4313404821 hasConceptScore W4313404821C170493617 @default.
- W4313404821 hasConceptScore W4313404821C203014093 @default.
- W4313404821 hasConceptScore W4313404821C2776070231 @default.
- W4313404821 hasConceptScore W4313404821C2778938600 @default.
- W4313404821 hasConceptScore W4313404821C511355011 @default.
- W4313404821 hasConceptScore W4313404821C544821477 @default.
- W4313404821 hasConceptScore W4313404821C71924100 @default.
- W4313404821 hasConceptScore W4313404821C98274493 @default.
- W4313404821 hasIssue "1_Supplement" @default.
- W4313404821 hasLocation W43134048211 @default.
- W4313404821 hasOpenAccess W4313404821 @default.
- W4313404821 hasPrimaryLocation W43134048211 @default.
- W4313404821 hasRelatedWork W1970287328 @default.
- W4313404821 hasRelatedWork W1992540782 @default.
- W4313404821 hasRelatedWork W2027913950 @default.
- W4313404821 hasRelatedWork W2050423574 @default.
- W4313404821 hasRelatedWork W2077993809 @default.
- W4313404821 hasRelatedWork W2080063393 @default.
- W4313404821 hasRelatedWork W2101411396 @default.
- W4313404821 hasRelatedWork W2531609953 @default.
- W4313404821 hasRelatedWork W2981576095 @default.
- W4313404821 hasRelatedWork W3116363985 @default.
- W4313404821 hasVolume "208" @default.
- W4313404821 isParatext "false" @default.
- W4313404821 isRetracted "false" @default.
- W4313404821 workType "article" @default.